Prosecution Insights
Last updated: November 12, 2026
Application No. 19/629,996

COMPOSITIONS AND METHODS FOR TREATING CANCER

Final Rejection §103
Filed
Mar 26, 2026
Priority
Mar 24, 2022 — provisional 63/323,339 +2 more
Examiner
GONZALEZ, LUISALBERTO
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Oncocube Therapeutics LLC
OA Round
2 (Final)
58%
Grant Probability
Moderate
3-4
OA Rounds
99%
With Interview

Examiner Intelligence

Grants 58% of resolved cases
58%
Career Allowance Rate
96 granted / 164 resolved
-1.5% vs TC avg
Strong +48% interview lift
Without
With
+48.3%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
63 currently pending
Career history
234
Total Applications
across all art units

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Detailed Action Response to amendments The amendments made to the claims 09/21/2026 have been entered. In view of the amendments made, the 102 rejections made in the non-final office action of 06/23/2026 have been modified. See rejections below. In view of the amendments made, the 112(b) rejection over claims 93-106, 108-109, 114-118, and 120 have been withdrawn. In view of the amendments the 112(b) and 112(d) rejections over claims 108-109 and 117-118 have been withdrawn. Terminal Disclaimer The terminal disclaimer over U.S. Patent 11,986,475 and co-pending application 18/849,309 is acknowledged. The non-statutory double patenting rejections made have been withdrawn. Information Disclosure Statement The third party submission and the information disclosure statement submitted 08/14/2026 and 09/21/2026, respectively, have been considered. Modified Rejections Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. KSR Rationales The MPEP in section 2143, subsection I gives examples of Rationales for supporting a conclusion of obvious. These rationales are non-exhaustive and include (A) Combining prior art elements according to known methods to yield predictable results; (B) Simple substitution of one known element for another to obtain predictable results; (C) Use of known technique to improve similar devices (methods, or products) in the same way; (D) Applying a known technique to a known device (method, or product) ready for improvement to yield predictable results; (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success; (F) Known work in one field of endeavor may prompt variations of it for use in either the same field or a different one based on design incentives or other market forces if the variations are predictable to one of ordinary skill in the art; (G) Some teaching, suggestion, or motivation in the prior art that would have led one of ordinary skill to modify the prior art reference or to combine prior art reference teachings to arrive at the claimed invention. Claim(s) 93-109, 111-114, 117-118, and 123 is/are rejected under 35 U.S.C. 103 as being unpatentable over Chu-Farseeva (European Journal of Medicinal Chemistry, 158, 2018, 593-619) in view of Böhm (ChemBioChem, 2004, 5, 637-643), Silverman (The Organic Chemistry of Drug Design and Drug Action, Academic Press, 1992), and Subbaiah (J. Med. Chem. 2021, 64, 14046-14128). Chu-Farseeva on p. 594, Figure 1 teaches compound XL019, shown below. XL019 PNG media_image1.png 280 192 media_image1.png Greyscale PNG media_image2.png 324 994 media_image2.png Greyscale Regarding the limitation “E”, claim 93 states that “E…are each independently aryl or heteroaryl”. The term “aryl” is defined in the specification as follows. PNG media_image3.png 286 984 media_image3.png Greyscale Claim 95 specifies the core structure below. PNG media_image4.png 208 290 media_image4.png Greyscale Claim 96 specifies the core structure below. PNG media_image5.png 216 300 media_image5.png Greyscale Claims 98-99, dependent upon claim 94, are drawn to compounds wherein the B ring system is a pyridine ring (claim 98: X5 is N and X6 is CR9, claim 99: X5 is CR8 and X6 is N). Claims 105 and 106, dependent upon claim 98, are drawn to compounds wherein R6, R7 and R9 are hydrogen (H). Claim 106 is drawn to a compound wherein the B ring is fluorinated at the R9 position and R6 and R7 are H. Regarding claim 95, only one of X1-X4 is nitrogen (pyridine ring). Regarding claim 96, the instant ring is a positional isomer of the reference ring. Regarding claims 98 and 99, which are dependent upon claim 94, the compound claim is essentially a pyridine ring (either X5 is nitrogen and X6 is nitrogen, or vice versa). This can be reached by simply modifying one carbon of the phenyl ring in XL019 to a nitrogen. Regarding claims 105 and 106, which are dependent upon claim 98, claim 105 is a simple pyridine ring and claim 106 is a fluorinated pyridine ring. One of ordinary skill in the art could achieve claim 98 by simply modifying the phenyl ring of XL019 to include one nitrogen in the ring. One of ordinary skill in the art could achieve the compound of 99 by further substituting the hydrogen corresponding to R9 to a fluorine atom. Motivation and reasoning to make these modifications is found in Böhm and Silverman, and Subbaiah. Böhm is drawn to methods of fluorination of medicinal compounds. Böhm in sec. Introduction teaches that fluorination of medicinal compounds can have an effect on the metabolic stability of a compound, can influence the basicity of a compound, and can increase the binding affinity of a medicinal compound. Böhm specifically states “There are many examples illustrating that the replacement of an oxidizable C-H group by a C-F group increases metabolic stability of the molecule”, that a fluorine atom “reduces basicity; this results in better membrane permeation of a compound,” and “increasingly, fluorine substituents are introduced to increase the binding affinity of a compound.” Böhm on p. 638, Scheme 1 and 2 depicts the effects of fluorinating a phenyl ring. Böhm Scheme 1 PNG media_image6.png 280 490 media_image6.png Greyscale Böhm Scheme 2 PNG media_image7.png 262 428 media_image7.png Greyscale Silverman on p. 19 states “Bioisosteres are substituents or groups that have chemical or physical similarities, and which produce broadly similar biological properties. Bioisosterism is a lead modification approach that has been shown to be useful to attenuate toxicity or to modify the activity of a lead, and it may have significant role in the alteration of metabolism of a lead.” Silverman in Table 2.2 lists the following biological equivalent bioisosteres. See 1. Univalent atoms and Groups 5. Ring Equivalents PNG media_image8.png 392 486 media_image8.png Greyscale Subbaiah on p. 14082, left col., para. 1 teaches to substitution of a meta-substituted phenyl ring. Subbaiah specifically states “A MMP analysis of the effects of replacing a 1,3-disubstituted benzene ring with azoles and azine on metabolic stability in HLM revealed furan…and thiophene… present a low probability of achieving advantage…However, in examples where a 3,5-1H-pyrazole, a 3,5-isoxazole, a (3,5)-1,2,4-oxadiazole, a 1,3,4-oxadiazole, a 2,4-1H-imidazole, or a 3,5-1H-1,2,4,-triazole…were deployed, these heterocycles offered enhanced metabolic stability indicated that these transforms represent useful substituted…For six-membered heterocycles, the three pyridine isomers…offered a similarly modest advantage, while a 3,5-pyrazine was poor despite a reduction in the LogD7.4 value”. These results are summarized in as differences in Δ CIint, HLM stability, and LogD7.4, shown below. PNG media_image9.png 373 488 media_image9.png Greyscale Note that the pyridine ring systems all provide similar modification when replacing a phenyl ring and that the pyridine rings are somewhat similar to the pyrazine ring system in 63p in terms of properties. Therefore, one of ordinary skill in the art would find it obvious to modify the pyrazine ring of Chu-Farseeva to instead have a pyridine ring system. Considering the above, the modifications necessary to achieve the instant compounds are within the skillset of one of ordinary skill and the motivation to make the modifications is also explicitly taught. Therefore, it would have been prima facie obvious at the time of the effective filing date for one of ordinary skill in the art to have modified the compound of Chu-Farseeva to arrive at the instant compound. One of ordinary skill would be motivated to make the modifications in efforts to optimize the pharmacological properties of the compound. Claim(s) 93, 97, 100-101, 103, 115-118, and 123 is/are rejected under 35 U.S.C. 103 as being unpatentable over Wang (US20190152954) in view of Subbaiah (J. Med. Chem. 2021, 64, 14046-14128). Regarding claims 93, 97, 100-101, 103, 110, and 115-118 Wang on p. 129, right col., discloses a compound with the following structure. PNG media_image10.png 198 242 media_image10.png Greyscale Where the compound above differs from the instant claims is that pyrazine ring is excluded from the instant claims. However, it would be obvious to modify the pyrazine ring to a pyridine ring in view of the teachings of Subbaiah. Subbaiah on p. 14082, left col., para. 1 teaches to substitution of a meta-substituted phenyl ring. Subbaiah specifically states “A MMP analysis of the effects of replacing a 1,3-disubstituted benzene ring with azoles and azine on metabolic stability in HLM revealed furan…and thiophene… present a low probability of achieving advantage…However, in examples where a 3,5-1H-pyrazole, a 3,5-isoxazole, a (3,5)-1,2,4-oxadiazole, a 1,3,4-oxadiazole, a 2,4-1H-imidazole, or a 3,5-1H-1,2,4,-triazole…were deployed, these heterocycles offered enhanced metabolic stability indicated that these transforms represent useful substituted…For six-membered heterocycles, the three pyridine isomers…offered a similarly modest advantage, while a 3,5-pyrazine was poor despite a reduction in the LogD7.4 value”. These results are summarized in as differences in Δ CIint, HLM stability, and LogD7.4, shown above. Therefore, it would have been prima facie obvious at the time of the effective filing date for one of ordinary skill in the art to have modified the compound of Wang via the teachings of Subbaiah to arrive at the instant claims with a reasonable assumption of success. One of ordinary skill would be motivated to make the modification as Subbaiah teaches that the pyrazine ring system shares similar properties with the pyridine ring system and it would be obvious to try in efforts for optimization of the compound. Allowable Subject Matter Claims 119-122 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion No claims allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LUISALBERTO GONZALEZ whose telephone number is (571)272-1154. The examiner can normally be reached M-F 8:30-5:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached at (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.G./Examiner, Art Unit 1624 /JEFFREY H MURRAY/Supervisory Patent Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Mar 26, 2026
Application Filed
Jun 23, 2026
Non-Final Rejection mailed — §103
Sep 21, 2026
Response Filed
Oct 16, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760058
PRODRUGS OF NEUROACTIVE STEROIDS
4y 1m to grant Granted Oct 13, 2026
Patent 12708620
PRODRUGS AND MEDICAL USES THEREOF
5y 8m to grant Granted Aug 18, 2026
Patent 12708622
METHODS OF TREATING CANCER AND INHIBITING TYK2 AND MEK
3y 9m to grant Granted Aug 18, 2026
Patent 12698271
CRYSTALLINE FORM OF A SHP2 INHIBITOR
2y 10m to grant Granted Aug 04, 2026
Patent 12662481
SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS
4y 5m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
58%
Grant Probability
99%
With Interview (+48.3%)
Moderate
PTA Risk
Based on 164 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month